€79.45
1.49% today
Madrid, Apr 02, 05:36 pm CET
ISIN
ES0169501022
Symbol
PHM
Sector
Industry

Pharma Mar Stock price

€79.45
-20.50 20.51% 1M
+32.85 70.49% 6M
-0.35 0.44% YTD
+51.59 185.18% 1Y
+5.53 7.48% 3Y
+23.58 42.20% 5Y
+30.67 62.87% 10Y
Madrid, Closing price Wed, Apr 02 2025
-1.20 1.49%
ISIN
ES0169501022
Symbol
PHM
Sector
Industry

Key metrics

Market capitalization €1.42b
Enterprise Value €1.31b
P/E (TTM) P/E ratio 54.31
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 7.51
P/S ratio (TTM) P/S ratio 8.11
P/B ratio (TTM) P/B ratio 6.80
Revenue growth (TTM) Revenue growth 10.56%
Revenue (TTM) Revenue €174.86m
EBIT (operating result TTM) EBIT €2.56m
Free Cash Flow (TTM) Free Cash Flow €-8.99m
Cash position €154.53m
EPS (TTM) EPS €1.48
P/E forward 21.24
P/S forward 7.12
EV/Sales forward 6.60
Show more

Is Pharma Mar a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Pharma Mar Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Pharma Mar forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a Pharma Mar forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from Pharma Mar

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
175 175
11% 11%
100%
- Direct Costs 10 10
7% 7%
6%
165 165
11% 11%
94%
- Selling and Administrative Expenses 52 52
6% 6%
30%
- Research and Development Expense 104 104
4% 4%
59%
9.34 9.34
2,178% 2,178%
5%
- Depreciation and Amortization 6.77 6.77
18% 18%
4%
EBIT (Operating Income) EBIT 2.56 2.56
148% 148%
1%
Net Profit 26 26
2,192% 2,192%
15%

In millions EUR.

Don't miss a Thing! We will send you all news about Pharma Mar directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.

Head office Spain
CEO José Sousa-Faro
Founded 1986
Website www.pharmamar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today